-
Mashup Score: 5demise of Roe v Wade: a hematologist’s perspective - 2 year(s) ago
The impact of the Dobbs v Jackson Women’s Health Organization decision by the US Supreme Court, removing federal protection of abortion rights, has important im
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5Defining and treating high-grade B-cell lymphoma, NOS - 2 year(s) ago
Edited by Associate Editor Laurie Sehn, this 3-part Review Series covers rare, aggressive B-cell lymphomas. First, Olszewski et al discuss a recently-designated
Source: American Society of HematologyCategories: Hematologists1, Latest HeadlinesTweet-
RT @DrAEvens: Defining and treating high-grade B-cell #lymphoma, NOS https://t.co/lderjcWpWx TY to @BrownMedicine @lymphomatic & @BrownUni…
-
-
Mashup Score: 2Home - 19th International Ultmann Chicago Lymphoma Symposium - 3 year(s) ago
The International Ultmann Chicago Lymphoma Symposium (IUCLS) is an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the…
Source: www.bioascend.infoCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @BioAscend: Register at https://t.co/UIDchY830q to hear the latest research & info on aggressive #lymphoma from Dr. David Scott, @lympho…
-
-
Mashup Score: 15
Key Points. The NGS-MRD assay detected clonotypic DNA in 100% of CSF samples from patients who had a B-cell lymphoma with parenchymal CNS involvementClonotypic
Source: ashpublications.orgCategories: Hematologists1, Latest HeadlinesTweet-
We detected clonotypic DNA in the CSF of 36% #DLBCL pts @ high CNS relapse risk. (+)CSF = 29% risk of CNS relapse, (-)CSF assay = 0% risk. If validated - maybe a new way to help personalize CNS prophylaxis? https://t.co/AJ9S3VCXpV #lymsm @BloodAdvances @AdaptiveBiotech @BrownHeme https://t.co/xGggHK3qRF
-
-
Mashup Score: 41Defining and Treating High-grade B-cell lymphoma, NOS | Blood | American Society of Hematology - 3 year(s) ago
High-grade B-cell lymphoma, not otherwise specified (HGBL, NOS) is a recently introduced diagnostic category for aggressive B-cell lymphomas. It includes tumors
Source: ashpublications.orgCategories: Latest Headlines, Oncologists1Tweet-
RT @DrAEvens: Defining and Treating High-grade B-cell #lymphoma, NOS | @BloodJournal @ASH_hematology https://t.co/zO87mZ7tkj Happy to pub…
-
-
Mashup Score: 2Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease - 3 year(s) ago
This retrospective case series study examines immune response of adults with hematologic malignant disease who were vaccinated with 1 of 3 FDA-authorized COVID-19 vaccines between February and April of 2021.
Source: jamanetwork.comCategories: Hematologists1, Latest HeadlinesTweet-
(2) Pts with #lymphoma have low responses to standard #CovidVaccine. + (2) CDC recommends #boosterdose for immunosuppressed = (4) If you had a CD20 antibody or are on active therapy for lymphoma, you're included. #lymsm @ASH_hematology @lymphoma https://t.co/trSCtUgydB https://t.co/piIGThSB5o
-
-
Mashup Score: 062nd ASH Annual Meeting and Exposition - 4 year(s) ago
The ASH annual meeting is the world’s most comprehensive hematology event of the year for an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates on the most critical topics in hematology.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Congrats Dr. @DiMengyang - great companion to your original work coming up tomorrow! https://t.co/sDoMU90osC #lymsm https://t.co/9EMN0uUsYF
-
-
Mashup Score: 1Learning Medicare’s ABCDs - 4 year(s) ago
Medicare was established to help provide affordable health care coverage for older Americans. But Medicare beneficiaries with cancer can still face financial burdens related to their care.
Source: www.cancertodaymag.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Great @AACR exposé of erratic Medicare coverage for oral cancer drugs. 14 years into Part D, still no clear plan how to fix loopholes and shady deals. Did I hear @JoeBiden say "negotiating power"? 🙂 Learning Medicare’s ABCDs https://t.co/3p17wExYnr @ASCO @ASH_hematology @ACSCAN
-
-
Mashup Score: 2Outcomes of bendamustine‐ or cyclophosphamide‐based first‐line chemotherapy in older patients with indolent B‐cell lymphoma - 5 year(s) ago
Clinical trials comparing bendamustine/rituximab (BR) with cyclophosphamide‐based regimens (RCHOP/RCVP) have pooled various histologies of indolent B‐cell lymphomas. We examined real‐life outcomes of…
Source: Wiley Online LibraryCategories: Hem/OncsTweet-
BR for indolent @lymphoma is less toxic & has better PFS than RCHOP/RCVP. But in real world: 33% of older pts are hospitalized, 14% in ICU, 21% with infection, and no OS benefit. It's still chemo, and it's not good enough. https://t.co/Ah9EYF9aLR #lymsm @ASH_hematology @LLSusa https://t.co/hvTJZB1Kgm
-
RT @BloodJournal: Editorial: The demise of Roe v Wade: a hematologist’s perspective https://t.co/h85d7TXep1